This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets analysed during the current study are available from the corresponding author on reasonable request.
References
Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53:1401–15.
Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382:1800–10.
Malagola M, Cancelli V, Skert C, Ferremi Leali P, Tiburzi A, sala ML, et al. Extracorporeal photopheresis for treatment of acute and chronic graft versus host disease: an italian multicentric retrospective analysis on 94 patients on behalf of the gruppo italiano trapianto di midollo osseo. Transplantation. 2016;100:147–55.
Pierelli L, Perseghin P, Marchetti M, Messina C, Perotti C, Mazzoni A, et al. Extracorporeal photopheresis for the treatment of acute and chronic graft-versus-host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process. Transfusion. 2013;53:2340–52.
Pierelli L, Bosi A, Olivieri A. “Best practice” for extracorporeal photopheresis in acute and chronic graft-versus-host disease by Societa’ Italiana di Emaferesi and Manipolazione Cellulare and Gruppo Italiano Trapianto Midollo Osseo: a national survey to ascertain its degree of application in Italian transplant centers. Transfusion. 2018;58:217–22.
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein UM, et al. Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level. Bone Marrow Transpl. 2020;55:2286–93.
Maas-Bauer K, Kiote-Schmidt C, Bertz H, Apostolova P, Wäsch R, Ihorst G, et al. Ruxolitinib–ECP combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transpl. 2021;56:909–16.
MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transpl. 2015;21:761–7.
Penack O, Peczynski C, Boreland W, Lemaitre J, Afanasyeva K, Kornblit B, et al. ECP versus ruxolitinib in steroid-refractory acute GVHD - a retrospective study by the EBMT transplant complications working party. Front Immunol. 2023; https://doi.org/10.3389/fimmu.2023.1283034.
Lastovytska I, Heidenreich S, Klyuchnikov E, Niederwieser C, Gagelmann N, Richter J, et al. Lower incidence of chronic graft-versus-host disease after ruxolitinib plus extracorporeal photopheresis versus ruxolitinib alone in steroid-refractory acute graft-versus-host disease following allogeneic stem cell transplantation. Haematologica; https://doi.org/10.3324/haematol.2024.286824.
Stolz D, Giesler S, Zeiser R. Two heads are better than one: a synergistic strategy for conquering graft-versus-host disease. Haematologica; https://doi.org/10.3324/haematol.2025.2877746.
MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatments trials. Blood. 2010;115:5412–7.
Penack O, Marchetti M, Aljurf M, Arat M, Bonifazi F, Duarte RF, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 2024;11:147–59.
Acknowledgements
The authors thank Lara Cox for the English revision.
Author information
Authors and Affiliations
Contributions
MLB and FP collected and analyzed the clinical data, wrote the manuscript and performed the bibliographic search; GF and CS contributed to design; EO, ED and AMG contributed to data source; MI and MDM performed statistical analysis; all other authors (PC, DR, MM, FS, GM, AR, IMC, AL, CN, AC, ML, VF, MCM, MTLS, MP, AB, FF, CS, AG, RF, FC, MM) contributed to revising the manuscript and approved the final version.
Corresponding author
Ethics declarations
Competing interests
FP participated in Advisory Board of Menarini, Sanofi, Bristol Meyer Squibb and received lecture honoraria from Johnson&Johnoson and Novartis. MTLS participated in Advisory Board of Novartis, Pfizer, consultancy Incyte, Sanofi, other (organization of scientific event) Therakos / Mallinkrodt. AL participated in AbbVie Speakers Bureau. All other authors declared no potential competing interests in relation to this study.
Ethics approval and consent to participate
Patient and transplant data were extracted from the European PROMISE database and additional queries were then submitted to each center to try to minimize missing data. All patients included in the study provided informed consent to data registration in the PROMISE database. The study, conducted in accordance with good clinical practice guidelines and regulations, was approved by the GITMO Trial Office and by the Institutional Review Board of Udine University (Prot. IRB 145/2024).
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Battista, M.L., Facchin, G., De Martino, M. et al. Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy. Bone Marrow Transplant (2025). https://doi.org/10.1038/s41409-025-02674-3
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-025-02674-3
